NASDAQ$AKYA

Akoya Biosciences Inc · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

Akoya reported record revenue driven by robust demand for its spatial biology solutions.

Akoya Biosciences reported a 31% increase in revenue for Q4 2022, reaching $21.2 million compared to $16.2 million in the prior year period. The company's product revenue increased by 22% to $15.7 million, while services and other revenue grew by 70% to $5.5 million. Gross profit was $12.0 million with a gross profit margin of 57%.

  • Total revenue reached $21.2 million, a 31% increase year-over-year.
  • Product revenue increased by 22% to $15.7 million.
  • Services and other revenue grew by 70% to $5.5 million.
  • Gross profit was $12.0 million with a gross profit margin of 57%.

Headline financials

Total Revenue

$21.2M

Previous: $16.2M+31.3%
EPS (adj)

-$0.50

Previous: -$0.47-6.4%
Capital Expenditures

$869K

Previous: $1.37M-36.3%
Free Cash Flow

-$10.9M

Previous: -$7.22M-50.7%
Net Income

-$18.9M

Previous: -$17.7M-6.8%
Operating Income

-$17.6M

Previous: -$16.8M-4.8%
Gross Profit

$12M

Previous: $10.2M+17.8%
Cash & Equivalents

$74.2M

Previous: $113M-34.4%
Total Assets

$176M

Previous: $191M-7.8%
Stock-Based Comp

$2.12M

Previous: $1.41M+50.2%

Revenue & EPS history

Akoya · Revenue · Quarterly

$21.2M

Q4 2022+31.3%vs Q4 2021
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Akoya · $21.2M total across 2 segments · Q4 2022

  • Product revenue
    $15.7M+21.6%
  • Service and other revenue
    $5.51M+70.3%

Forward guidance

The Company expects a full year 2023 revenue guidance range of $95-98 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 10 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

-3.7%

Avg return

Earnings day

-8.6%

Avg return

5 days after

-17.2%

Avg return

30 days after

53%

10 / 19 earnings

Positive

+13.7%

Q4 2021

Best reaction

-31.9%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025
Q2 2025
Q1 2025+1.0%+24.8%+23.8%
Q4 2025+3.8%+9.2%-30.7%
Q3 2024-24.9%-33.2%-29.5%
Q2 2024-9.5%-0.9%+5.5%
Q1 2024-31.9%-35.1%-50.0%
Q4 2023-15.4%-17.1%-28.1%
Q3 2023+10.0%+6.9%+16.4%
Q2 2023+0.9%-6.5%-23.9%
Q1 2023-2.5%-17.1%-18.8%
Q4 2022-7.3%-17.2%-36.6%
Q3 2022-15.1%
Q2 2022+5.0%
Q1 2022-11.9%
Q4 2021+13.7%
Q3 2020+1.5%
Q3 2021+0.2%
Q2 2021-0.1%
Q4 2020+9.5%
Q1 2021+2.3%
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro